FIX activated complex anti-inhibitor coagulant complex FEIBA
Selected indexed studies
- FEIBA: mode of action. (Haemophilia, 2004) [PMID:15385040]
- FEIBA safety profile in multiple modes of clinical and home-therapy application. (Haemophilia, 2004) [PMID:15385041]
- Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy. (Haemophilia, 2016) [PMID:26879158]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- FEIBA: mode of action. (2004) pubmed
- FEIBA safety profile in multiple modes of clinical and home-therapy application. (2004) pubmed
- Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy. (2016) pubmed
- Surgery in haemophilic patients with inhibitor: 20 years of experience. (2004) pubmed
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. (2010) pubmed
- Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. (2014) pubmed
- Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. (1992) pubmed
- A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. (2003) pubmed
- Cases of surgery in high-responder haemophilia patients. (2004) pubmed
- Factor VIII Bypassing Activity (FEIBA) assays: standardization and development of the 1st NIBSC Working Standard for FEIBA--results from a collaborative study. (2013) pubmed